search
Back to results

Interference of Biotin Supplementation in Biotin-streptavidin Platforms for Hormone Testing

Primary Purpose

Thoracic Diseases, Parathyroid Diseases

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
biotin
Sponsored by
University of Minnesota
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Thoracic Diseases focused on measuring biotin pharmacokinetic, biotinylated assay, hormone measurement, thyroid, parathyroid, prolactin

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Healthy adults

Exclusion Criteria:

  1. Pregnancy or lactation
  2. Known thyroid disease (goiter, abnormal thyroid state),
  3. Thyroid hormone treatment,
  4. Over the counter dietary/ nutritional supplement use currently or within the last 2 weeks (excluding standard multivitamin preparations containing no more than 100% of the daily value for biotin and calcium),
  5. Anticonvulsants,
  6. Night shift work, smokers, adults lacking capacity to consent for themselves

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Biotin arm

    Arm Description

    biotin 10 mg/day for 7 days

    Outcomes

    Primary Outcome Measures

    Hormone measurements TSH, PTH, Total T4, free T4, total T3, free T3, prolactin
    Hormone measurements using biotinylated assay conducted in certified labratory using the standard lab ranges for each test.

    Secondary Outcome Measures

    Full Information

    First Posted
    January 17, 2017
    Last Updated
    April 17, 2019
    Sponsor
    University of Minnesota
    Collaborators
    Johns Hopkins University, Boston Medical Center, Children's Mercy Hospital Kansas City
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03034707
    Brief Title
    Interference of Biotin Supplementation in Biotin-streptavidin Platforms for Hormone Testing
    Official Title
    Interference of Biotin Supplementation in Biotin-streptavidin Platforms for Hormone Testing
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2019
    Overall Recruitment Status
    Completed
    Study Start Date
    April 2016 (undefined)
    Primary Completion Date
    October 2016 (Actual)
    Study Completion Date
    December 31, 2018 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    University of Minnesota
    Collaborators
    Johns Hopkins University, Boston Medical Center, Children's Mercy Hospital Kansas City

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The B vitamin biotin is widely available as an over the counter supplement, often advertised and used to promote health of hair, skin and nails. Commercially available over the counter biotin supplements contain dose ranges up to 10 mg/day (ie 333 times higher than the recommended dietary allowance). The biotin molecule is also sometimes used as part of the lab technology to measure hormone and protein levels in the blood. It is possible that high doses of ingested biotin may interfere with accurate hormone or protein measurement using biotin related in vitro measurement systems. Such interference, if present, could lead to misdiagnosis. The study will analyze laboratory levels obtained with streptavidin-biotin assay systems while ingesting biotin in currently available high dose supplements. The data will be compared to measurements obtained prior to and one week after stopping the biotin supplement.
    Detailed Description
    Specimens will be collected by venipuncture at 3 time points, including baseline (time 0), after one week of biotin supplementation (time 1, day 7), and then one week later (time 2, day 14). The time 1 specimen will be drawn approximately 2 hours after the last ingested dose of biotin on day 7. Specimen collection will include three 10 ml red top (no gel) tubes at each timepoint. Specimens will be separated for isolation of serum using routine methods of the clinical chemistry laboratory. Serum will be stored at -80 degrees C until batch measurements as described Measurements Biotin levels will be measured on each sample. Hormone measurements will be performed using specific commercially available streptavidin-biotin assays and using different analyzers as indicated below. Immunoassay methods, not employing biotin-streptavidin methodology, will be used for negative assay controls.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Thoracic Diseases, Parathyroid Diseases
    Keywords
    biotin pharmacokinetic, biotinylated assay, hormone measurement, thyroid, parathyroid, prolactin

    7. Study Design

    Primary Purpose
    Other
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    12 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Biotin arm
    Arm Type
    Experimental
    Arm Description
    biotin 10 mg/day for 7 days
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    biotin
    Primary Outcome Measure Information:
    Title
    Hormone measurements TSH, PTH, Total T4, free T4, total T3, free T3, prolactin
    Description
    Hormone measurements using biotinylated assay conducted in certified labratory using the standard lab ranges for each test.
    Time Frame
    Change from baseline, at 7 days, at 14 days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    70 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Healthy adults Exclusion Criteria: Pregnancy or lactation Known thyroid disease (goiter, abnormal thyroid state), Thyroid hormone treatment, Over the counter dietary/ nutritional supplement use currently or within the last 2 weeks (excluding standard multivitamin preparations containing no more than 100% of the daily value for biotin and calcium), Anticonvulsants, Night shift work, smokers, adults lacking capacity to consent for themselves
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Lynn A Burmeister, MD
    Organizational Affiliation
    Univ of Minnesota
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Angela Radulescu, MD
    Organizational Affiliation
    Univ of Minnesota
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    11800048
    Citation
    Fiume MZ; Cosmetic Ingredient Review Expert Panel. Final report on the safety assessment of biotin. Int J Toxicol. 2001;20 Suppl 4:1-12.
    Results Reference
    background
    PubMed Identifier
    19717659
    Citation
    Meany DL, Jan de Beur SM, Bill MJ, Sokoll LJ. A case of renal osteodystrophy with unexpected serum intact parathyroid hormone concentrations. Clin Chem. 2009 Sep;55(9):1737-9. doi: 10.1373/clinchem.2008.121921. No abstract available.
    Results Reference
    background
    PubMed Identifier
    22437752
    Citation
    Kwok JS, Chan IH, Chan MH. Biotin interference on TSH and free thyroid hormone measurement. Pathology. 2012 Apr;44(3):278-80. doi: 10.1097/PAT.0b013e3283514002. No abstract available.
    Results Reference
    background
    PubMed Identifier
    23089740
    Citation
    Wijeratne NG, Doery JC, Lu ZX. Positive and negative interference in immunoassays following biotin ingestion: a pharmacokinetic study. Pathology. 2012 Dec;44(7):674-5. doi: 10.1097/PAT.0b013e32835a3c17. No abstract available.
    Results Reference
    background
    PubMed Identifier
    28973622
    Citation
    Li D, Radulescu A, Shrestha RT, Root M, Karger AB, Killeen AA, Hodges JS, Fan SL, Ferguson A, Garg U, Sokoll LJ, Burmeister LA. Association of Biotin Ingestion With Performance of Hormone and Nonhormone Assays in Healthy Adults. JAMA. 2017 Sep 26;318(12):1150-1160. doi: 10.1001/jama.2017.13705.
    Results Reference
    derived

    Learn more about this trial

    Interference of Biotin Supplementation in Biotin-streptavidin Platforms for Hormone Testing

    We'll reach out to this number within 24 hrs